Loading
BriaCell Therapeutics Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Lustig Marc, was filed 20 May 2024.
BriaCell Therapeutics Corp.: what insiders have been doing
BriaCell Therapeutics Corp. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). From 23 October 2025 to 23 October 2026, the disclosure feed for BriaCell Therapeutics Corp. logged 34 filings by 10 insiders.
Open-market activity splits into 2 purchases totalling €22k and 3 sales totalling €5.7M; 1 insider sit on the buying side and 1 insider on the selling side. The net balance comes to €5.7M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €5.4M, the sale published on 24 September 2026 by Lustig, Marc is the largest of the period. Those buying include 1 senior executive.
Compared with its exchange (3,167 companies, median 24 filings), a count of 34 filings is above the norm. The full history, which starts in 2016, counts 75 purchases against 14 sales. The 10-K for the year ended 31 July 2025 shows -26.3 m USD of net income.
The clock since the last published purchase (26 November 2025) now reads 332 days. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
176
Thresholds
n/a
Buy Volume
€3M
75 ops. · all time
Sell Volume
€6M
14 ops. · all time
Who traded when
BuySaleMarc Lustig1 buy
Since the insiders bought
- +138.3%Entry US$14.90 · Close at T+365 US$35.50
- +30.0%Entry US$45.00 · Close at T+365 US$58.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2024FY ended July 2024 · cache
US$3.46
Analyst consensus
Income statement
EBITDA-US$4.8M
Net income-US$4.8M0.0% margin
Valuation
P/Book1.0x
Beta1.51
Balance sheet & cash
Market capUS$30.1M
Total debtUS$26k
Free Cash Flow-US$24.6M
Profitability & ownership
ROE-175.3%
ROA-90.8%
% insiders0.0%
% institutions6.4%
Last declaration on 28 September 2026
Declarations176 total
8,242 sharesPerformance Share UnitsTSXSEDI:4782198
25,257 sharesPerformance Share UnitsTSXSEDI:4782195
84,775 sharesPerformance Share UnitsTSXSEDI:4782194
94,194 sharesPerformance Share UnitsTSXSEDI:4782192
Performance Share UnitsTSXSEDI:4782190
59,613 sharesCommon SharesTSXSEDI:4782175
84,774 sharesPerformance Share UnitsTSXSEDI:4782170
254,329 sharesPerformance Share UnitsTSXSEDI:4782168
282,586 sharesPerformance Share UnitsTSXSEDI:4782166
Performance Share UnitsTSXSEDI:4782164
28,257 sharesPerformance Share UnitsTSXSEDI:4782162
84,775 sharesPerformance Share UnitsTSXSEDI:4782160
94,194 sharesPerformance Share UnitsTSXSEDI:4782159
Performance Share UnitsTSXSEDI:4782155
20,000 shares@ CA$3.387Common SharesTSXSEDI:4781368
1,000,000 shares@ CA$7.845Common SharesTSXSEDI:4781367
43,887 shares@ CA$7.845Common SharesTSXSEDI:4781366
56,517 sharesPerformance Share UnitsTSXSEDI:4781151
169,551 sharesPerformance Share UnitsTSXSEDI:4781147
188,390 sharesPerformance Share UnitsTSXSEDI:4781143
Performance Share UnitsTSXSEDI:4781140
Performance Share UnitsTSXSEDI:4781139
300,000 sharesRestricted Share UnitsTSXSEDI:4748127
300,000 sharesCommon SharesTSXSEDI:4748088
28,257 sharesCommon SharesTSXSEDI:4748080
25 of 176 declarations
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a biopharmaceutical company focused on developing immunotherapeutic treatments for cancer. It specializes in dendritic cell-based therapies to target tumors.
